(Q36945991)

17 August 2017

1 reference

title

Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis? (English)

1 reference

17 August 2017

0 references

F S Lienau

1

1 reference

17 August 2017

H Füllgraf

series ordinal

2

1 reference

17 August 2017

A Moser

series ordinal

3

1 reference

17 August 2017

T J Feuerstein

series ordinal

4

1 reference

17 August 2017

publication date

1 October 2007

1 reference

European Journal of Neurology

17 August 2017

published in

1 reference

17 August 2017

volume

14

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1162-1169

1 reference

Chronic pain secondary to disability: a review

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Acquired channelopathies in nerve injury and MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Nabilone in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

The molecular logic of endocannabinoid signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Retrograde signaling at GABAA-receptor synapses in the mammalian CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

21 January 2018

Cannabis and the brain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Cannabinoid receptor localization in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Cannabinoids: a real prospect for pain relief?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid typ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

The neurobiology of cannabinoid analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Anandamide: some like it hot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01903.X

10.1111/J.1468-1331.2007.01903.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference